COVID-19 Outcomes in Hospitalized Patients With Neurodegenerative Disease: A Retrospective Cohort Study.

Autor:	Patel RA; Department of Neurological Sciences (RAP, GTS, BB), Rush University Medical Center, Chicago, IL; Bioinformatics and Biostatistics Core (EBK), Rush University Medical Center, Chicago, IL; and Neurology Service (BB), Jesse Brown Veterans Affairs Medical Center, Chicago, IL., Stebbins GT; Department of Neurological Sciences (RAP, GTS, BB), Rush University Medical Center, Chicago, IL; Bioinformatics and Biostatistics Core (EBK), Rush University Medical Center, Chicago, IL; and Neurology Service (BB), Jesse Brown Veterans Affairs Medical Center, Chicago, IL., Kishen EB; Department of Neurological Sciences (RAP, GTS, BB), Rush University Medical Center, Chicago, IL; Bioinformatics and Biostatistics Core (EBK), Rush University Medical Center, Chicago, IL; and Neurology Service (BB), Jesse Brown Veterans Affairs Medical Center, Chicago, IL., Barton B; Department of Neurological Sciences (RAP, GTS, BB), Rush University Medical Center, Chicago, IL; Bioinformatics and Biostatistics Core (EBK), Rush University Medical Center, Chicago, IL; and Neurology Service (BB), Jesse Brown Veterans Affairs Medical Center, Chicago, IL.
Jazyk:	angličtina
Zdroj:	Neurology. Clinical practice [Neurol Clin Pract] 2022 Feb; Vol. 12 (1), pp. 43-51.
DOI:	10.1212/CPJ.0000000000001117
Abstrakt:	Background and Objectives: COVID-19 outcomes in patients with neurodegenerative disorders (NDs) are not well understood, and we hypothesize that there may be increased morbidity and mortality in this group. Methods: This was a retrospective cohort study performed at 3 hospitals in the Chicagoland area. All patients hospitalized with COVID-19 infection with ND during a 3-month period (March 15, 2020-June 15, 2020) were included and compared with age-matched controls (CL) at 1:1 ratio. Primary outcomes were death, intensive care unit (ICU) admission, and invasive ventilation. Secondary outcomes included presenting COVID-19 symptoms, development of encephalopathy, supplementary oxygen use, discharge disposition, and risk factors for mortality. Results: The study included 132 patients with neurodegenerative disorders and 132 age-matched CL. Ninety-day mortality (ND 19.7% vs CL 23.5%, p = 0.45) and ICU admission (ND 31.5% vs CL 35.9%, p = 0.43) rates were not significantly different between the 2 groups. Patients with ND had a lower rate of invasive ventilation (ND 11.4% vs CL 23.2%, p = 0.0075) and supplementary oxygen use (ND 83.2% vs CL 95.1%, p = 0.0012). Patients with ND were also more likely to have altered mental status or confusion as their presenting COVID-19 symptom and less likely to present with respiratory symptoms. Patients with ND were discharged to nursing home or hospice at higher rates compared with CL. Discussion: We found that there was no difference in short-term mortality of patients with ND hospitalized for COVID-19 compared with CL, but they may have higher rates of neurologic complications and disability. Future studies should address long-term outcomes. (© 2021 American Academy of Neurology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu